Samarth Kulkarni

Insider Reports History

Identity Names, identifiers, and filing context for this profile. 1 identity field
Reporting-owner location
Cambridge, MA
SEC source record Original filing metadata and source links for verification. 1 source field
Latest reporting-owner signature
/s/ Brent Hatzis-Schoch, Attorney-in-Fact
Source: Latest parsed Forms 3/4/5 signature
Source evidence Original filing metadata and source links for verification. 1 source field
Transaction source note
Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for Samarth Kulkarni

Form 4 holding Chief Executive Officer, Director

CRISPR Therapeutics AG

Security class
Stock Option (Right to Buy)
Shares / value
114,249
Estimated value
Report date
20 Mar 2026
Price
Ownership
Direct
Underlying class
Common Shares
Underlying amount
Form 4 holding Chief Executive Officer, Director

CRISPR Therapeutics AG

Security class
Restricted Stock Units
Shares / value
39,375
Estimated value
Report date
20 Mar 2026
Price
Ownership
Direct
Underlying class
Common Shares
Underlying amount
Form 4 holding Director

Repare Therapeutics Inc.

Security class
Stock Option (right to buy)
Shares / value
27,200
Estimated value
Report date
17 Jun 2024
Price
Ownership
Direct
Underlying class
Common Shares
Underlying amount

Insider Reports Filed by Samarth Kulkarni

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .